Fair enough although at some point we have to start looking beyond Covid. if it’s correct from other posts I’ve seen here that they’ve only very recently hired sales account and other staff in the main European countries then that explains the lack of sales. I’ve never seen any product sell if there’s nobody to actually sell it (maybe apart from Covid vaccine) the HDE is proving a bit too slow and that can’t be blamed on Covid. This appendix 4c they say they are finalising data package for fda, which is exactly what they said in last 4C. So that’s up to 6 months spent on “finalising”. What they’re finalising isn’t clear. At some point gotta stop finalising and actually send it in!
somebody else here posted a link to paper written by doctors in ? Adelaide about their OncoSil experience, surprised Osl didn’t publicise this more.
OSL Price at posting:
9.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)